Wide Ranks

HCM

HUTCHMED (China) Limited

18.43

Top Statistics
Market Cap 3 B Forward PE 94.38 Revenue Growth -42.60 %
Current Ratio 2.81 Trailing PE 0.0000 Earnings Growth -84.20 %
Profit Margins -6.87 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -136.58 Enterprise / Revenue 24.63 Price To Sales Trailing12 Months 5.16
Profitability
Profit Margins -6.87 % Operating Margins -9.00 %
Balance Sheet
Total Cash 803 M Total Cash Per Share 0.9400 Total Debt 88 M
Total Debt To Equity 11.78 Current Ratio 2.81 Book Value Per Share 0.8660
All Measures
Short Ratio 553.00 % Message Board Id finmb_26652603 Fax 852 2128 1778
Shares Short Prior Month 685021 Return On Equity -0.0544 City Hong Kong
Uuid 449b4879-f77b-3306-a602-ec54c57e4c31 Previous Close 17.38 First Trade Date Epoch Utc 1 B
Book Value 0.8660 Beta 0.7460 Total Debt 88 M
Volume 58042 Price To Book 21.28 Fifty Two Week Low 11.93
Total Cash Per Share 0.9400 Total Revenue 610 M Shares Short Previous Month Date 1 B
Target Median Price 27.65 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -9.00 % Target Mean Price 28.53 Net Income To Common -41970000
Implied Shares Outstanding 178 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 56980 Average Volume10days 56980 Total Cash 803 M
Next Fiscal Year End 1 B Revenue Per Share 3.58 Held Percent Insiders 0.0013
Ebitda Margins -18.03 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 17.38 Target Low Price 17.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 18.84 Open 18.29
Free Cashflow -59209376 Dividend Yield 0.00 % Return On Assets -0.0590
Time Zone Short Name EST Trailing Eps -0.2500 Day Low 18.29
Address1 Cheung Kong Center Shares Outstanding 170 M Price Hint 2
Target High Price 40.40 Website https://www.hutch-med.com 52 Week Change -0.0441
Average Volume 93439 Earnings Quarterly Growth -84.70 % Forward Eps 0.1400
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 265.60 %
Is_sp_500 False Regular Market Day High 18.57 Profit Margins -6.87 %
Debt To Equity 11.78 Fifty Two Week High 21.92 Day High 18.57
Shares Short 532100 Regular Market Open 18.29 Industry Key drug-manufacturers-specialty-generic
Earnings Growth -84.20 % Enterprise To Revenue 24.63 Revenue Growth -42.60 %
Shares Percent Shares Out 0.0031 Operating Cashflow -46977000 Currency USD
Time Zone Full Name America/New_York Market Cap 3 B Is_nasdaq_100 False
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name HUTCHMED (China) Limited
Regular Market Day Low 18.29 Held Percent Institutions 0.0429 Current Price 18.43
Address2 48th floor 2 Queen's Road Central Enterprise To Ebitda -136.58 Financial Currency USD
Current Ratio 2.81 Gross Margins -7.77 % Industry Disp Drug Manufacturers - Specialty & Generic
Number Of Analyst Opinions 12 Country Hong Kong Float Shares 515 M
Two Hundred Day Average 18.04 Enterprise Value 15 B Price To Sales Trailing12 Months 5.16
Forward PE 94.38 Regular Market Volume 58042 Ebitda -110153000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.

The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms.

It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd.

, Inmagene Biopharmaceuticals Co.

Ltd.

, Innovent Biologics Co.

, Inc., Genor Biopharma Co.

Ltd.

, Shanghai Junshi Biosciences Co.

Ltd.

, and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021.

HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.